dr. maddocks on the role of zanubrutinib in b-cell malignancies
Published 4 years ago • 112 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
2:02
dr. allan on the use of vecabrutinib therapy in b-cell malignancies
-
1:34
mazyar shadman, md, on the efficacy & tolerability of zanubrutinib in b-cell malignancies
-
1:33
zanubrutinib in acalabrutinib-intolerant patients with various b-cell malignancies
-
2:44
safety and efficacy of zanubrutinib in patients with b-cell malignancies
-
1:08
dr. maddocks on remaining challenges in follicular lymphoma
-
1:16
dr. maddocks on ongoing sequencing challenges in dlbcl
-
1:45
dr. ma on first- and second-generation btk inhibitors in b-cell malignancies
-
47:23
lymphoplasmacytic neoplasms: cases and differentials
-
5:00
beigene’s brukinsa (zanubrutinib): a newly approved treatment medicine for mantle cell lymphoma (mcl
-
23:27
shiv pillai (harvard) 2: bruton tyrosine kinase signaling
-
42:50
dr giselle sholler, dfmo, when & how it is used
-
1:10
dr. maddocks on emerging therapies in follicular lymphoma
-
1:00
dr. leslie on the utility of btk inhibitors in b-cell malignancies
-
1:22
dr. leslie on sequencing zanubrutinib in mcl
-
1:32:21
solving the puzzles for b-cell malignancies: navigating the place of btk inhibitors today and tom...
-
0:54
dr. ghosh on approved btk inhibitors in b-cell malignancies
-
1:33
btki inhibitors in the treatment of b-cell lymphoma - introduction
-
1:27
exploring questions remaining for btk inhibitors and b-cell malignancies
-
3:53
targeting btk in b-cell malignancies
-
1:29
dr. shadman presents on the use of zanubrutinib in btk inhibitor-intolerant patients at ash 2021
-
4:24
catherine coombs, md, discusses the safety of prolonged pirtobrutinib in b-cell malignancies
-
3:36
distinguishing features among btk inhibitors